4.6 Article

Rare Genetic Disorders: Novel Treatment Strategies and Insights Into Human Biology

期刊

FRONTIERS IN GENETICS
卷 12, 期 -, 页码 -

出版社

FRONTIERS MEDIA SA
DOI: 10.3389/fgene.2021.714764

关键词

TP63; ectodermal dysplasia; orphan (rare) diseases; rare genetic disorders; gene therapy; protein therapy; iPSC disease modeling

资金

  1. National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
  2. National Eye Institute (NEI) of the National Institutes of Health (NIH) [R01AR072621, R21EY029081]
  3. National Foundation for Ectodermal Dysplasias (NFED)

向作者/读者索取更多资源

Innovative ideas for treating genetic disorders have emerged in the past decade, with gene and protein replacement therapies, stem cell approaches like iPSC technology, and genome editing techniques leading the way. While promising for monogenetic disorders affecting single organs, challenges remain for diseases that affect multiple tissues and organs simultaneously. Solutions may lie in correcting phenotypes in the most severely affected tissues.
The last decade has seen a dramatic increase in innovative ideas for the treatment of genetic disorders for which no curative therapies exist. Gene and protein replacement therapies stand out as novel approaches to treat a select group of these diseases, such as certain tissue fragility disorders. Further, the advent of stem cell approaches, such as induced pluripotent stem cells (iPSC) technology, has led to the development of new methods of creating replacement tissues for regenerative medicine. This coincided with the discovery of genome editing techniques, which allow for the correction of disease-causing mutations. The culmination of these discoveries suggests that new and innovative therapies for monogenetic disorders affecting single organs or tissues are on the horizon. Challenges remain, however, especially with diseases that simultaneously affect several tissues and organs during development. Examples of this group of diseases include ectodermal dysplasias, genetic disorders affecting the development of tissues and organs such as the skin, cornea, and epithelial appendages. Gene or protein replacement strategies are unlikely to be successful in addressing the multiorgan phenotype of these diseases. Instead, we believe that a more effective approach will be to focus on correcting phenotypes in the most severely affected tissues. This could include the generation of replacement tissues or the identification of pharmaceutical compounds that correct disease pathways in specific tissues.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据